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Abstract: About half of patients with gastroesophageal reﬂ  ux disease (GERD) have a normal 
endoscopy, so symptom assessment is the only appropriate outcome measure for these persons. 
Symptom assessment is also of great importance in persons with erosive esophagitis. There 
is currently no fully validated questionnaire to compare symptom response to treatment of 
patients with GERD. The aim of this review is to consider ReQuest™ assessment tool to evaluate 
esophageal, supra-esophageal, and infra-esophageal symptoms, as well as any modiﬁ  cation of 
the patient’s quality of life. The ReQuest™ may be combined with the Los Angeles classiﬁ  ca-
tion of esophagitis (LA A-D), to include the normal endoscopic ﬁ  nding in normal endoscopy 
reﬂ  ux disease. The ReQuest™ score declines rapidly towards normal with patient treatment with 
a proton pump inhibitor. A proportion of patients need more than the usual 8 weeks of therapy. 
For example, in GERD patients with Los Angeles B-D, the ReQuest™ score falls more with 
pantoprazole 40 mg than with esomoprazole 40 mg after 12 weeks of therapy. Now that the 
simpliﬁ  ed ReQuest in Practice™ is available, this validated brief questionnaire has potential as 
an instrument for use in GERD patients seen in everyday clinical practice.
Keywords: complete healing, dyspepsia, erosive esophagitis, GERD symptoms, pH, 
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Introduction
In a review of the impact of proton pump inhibitors (PPIs) on the symptomatology of 
gastroesophageal reﬂ  ux disease (GERD) symptoms, one would not expect the need to 
return ﬁ  rst to basics to reﬁ  ne a deﬁ  nition of terms. But, that is exactly what is needed 
in order to be more precise in considering just what it is that we mean by the symp-
tomatology of GERD. The major challenge in the assessment of the effect of PPIs on 
GERD symptoms is to use the appropriate measurement tool. This tool must account 
for all GERD-related symptoms as well as Quality of Life (Q of L) issues, it must be 
reproducible, and be sensitive enough to measure therapy-associated changes.
The ReQuest™ scale has become increasingly used in clinical trials for the purpose 
of demonstrating possible superiority in symptom relief between PPIs. However, this 
ReQuest™ assessment tool assessment tool is also useful to demonstrate the high efﬁ  -
ciency of all PPIs in the amelioration of GERD symptoms in clinical practice (Rubin 
et al 2008). Additional concepts that have developed from this research program include 
complete healing, ie, complete resolution of GERD-associated symptoms as well as 
the healing of any associated erosive esophagitis (EE). A further concept is that the 
acute course of therapy may need to be extended from the usual 4–8 weeks (chosen to 
achieve higher rates of healing of EE) to 12 weeks in order to obtain not just healing 
of EE, but equally importantly to resolve all GERD symptoms.
It has been reported that about 44% of the US population have GERD-related 
symptoms once a month, and 20% once a week (Nebel et al 1976; Gallup 1988; Locke 
et al 1997; Fass et al 2001). GERD affects 10%–30% of otherwise healthy persons Therapeutics and Clinical Risk Management 2008:4(6) 1186
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in other Western countries (Stanghellini et al 2004), and 
the economic impact of treating these persons is enormous. 
To sufferers of GERD, these unfortunate persons are only 
too aware of the plethora of symptoms, be these related to 
acid, other upper gastrointestinal (GI) symptoms, supra- 
(extra-) esophageal complaints, those related to the lower 
GI tract, or to impaired quality of life (Q of L) from issues 
such as loss of nighttime sleep. Persons with GERD have 
signiﬁ  cantly (p  0.05) poorer health related quality of life 
than do the general population (Pare et al 2003), patients 
with diabetes or hypertension (Enck et al 1999), or patients 
with severe angina pectoris or mild cognitive heart failure 
(Dimenas et al 1993). Improvement of the Q of L in GERD 
is proportional to the frequency and sensitivity of esophageal 
or non-esophageal symptoms, irrespective of ﬁ  ndings on 
esophagogastroduodenoscopy (EGD) (Dimenas et al 1996; 
Dent et al 1999; Kaplan-Machlis et al 1999; Malfertheiner 
et al 2006).
Although there are over 1000 clinical studies of the 
use of the various proton pump inhibitors (PPIs) available 
worldwide, it is only in the past 5 years that the primary 
outcome response has become the multitude of symptoms 
arising from GERD, and not just the most common symptoms 
of heartburn and regurgitation so often the symptom focus 
in clinical studies of GERD. In retrospect, it is difﬁ  cult to 
understand how this had not come about sooner. Indeed, for 
the longest time the primary outcome assessment in clinical 
studies was the healing of  EE.
Only when community endoscopic studies of the 
prevalence of conditions associated with dyspepsia were 
performed did we begin to recognize more fully that while 
peptic ulcer disease (PUD) was disappearing, GERD with 
or without EE was becoming the commonest cause of 
dyspepsia. Yet, some patients with typical heartburn and 
regurgitation had a completely normal endoscopy. Over 
time, this concept became further modiﬁ  ed by the recog-
nition that the sensitivity of optical endoscopy could be 
improved with magniﬁ  cation, and that some persons with 
“endoscopy normal reﬂ  ux disease” (ENRD), also known as 
“normal endoscopy reﬂ  ux disease” (NERD), had pathologi-
cal changes on esophageal biopsy. Perhaps it would have 
been more appropriate if NERD had been “non-erosive 
reﬂ  ux disease”. So, the PUD-associated focus on the ulcer 
was transferred to the assessment of the severity of  EE, but 
the acceptance of NERD as part of the legitimate spectrum 
of GERD forced the initially somewhat grudging acceptance 
of the importance of symptoms in assessing the role of PPIs 
in all persons with GERD.
What is GERD?
What is GERD? GERD is “…a chronic, relapsing disease 
that infrequently progresses but is associated with a range 
of potentially serious esophageal complications (esophageal 
ulcer, esophageal stricture, Barrett’s esophagus or esopha-
geal cancer) and extra-esophageal diseases such as respira-
tory problems, chest pain, angina, and increased mortality” 
(Ruigomez et al 2004; Sontag et al 2006; Scholten et al 
2007). Other authors have suggested that GERD is “a con-
dition which develops when the reﬂ  ux of stomach contents 
causes troublesome symptoms and/or complications” (Vakil 
et al 2006). The more recent Montreal consensus deﬁ  nition 
states that GERD is “a condition that develops when the 
reﬂ  ux of gastric contents causes troublesome symptoms, 
impairs quality of  life (Q of  L) or leads to mucosal damage or 
complications”. Symptoms of GERD may overlap with func-
tional dyspepsia (FD) and irritable bowel syndrome (IBS) 
(Quigley et al 2007), so these must be taken into account 
as possible GERD-associated symptoms. Indeed, IBS-like 
symptoms are seen in 19%–71% of persons with GERD, and 
GERD-like symptoms are seen in 33%–75% of persons with 
IBD. It is speculated that this overlap may be due to visceral 
hypersensitivity in GERD, FD, and IBS (Bardhan et al 2004a; 
Beckerling et al 2004; Achim et al 2005a, b).
What are the optimal outcome 
measures to assess GERD 
treatment?
The recently developed ReQuest™ assessment of symptoms 
of GERD, and its amalgamation with the Los Angeles (LA) 
classiﬁ  cation of erosive esophagitis (EE) have been used to 
provide an assessment tool which led to the development of 
a new concept in GERD, that of “complete healing.” What is 
so new about “complete healing” in GERD? It is recognized 
that from a symptom perspective, GERD is much more than 
heartburn and regurgitation: in GERD there are esophageal, 
supra-esophageal as well as infra-esophageal symptoms, all 
contributing to the patient’s impaired Q of L.
In addition, there is a disassociation between the sever-
ity of the patient’s dyspeptic symptoms, and the severity of 
the underlying EE; in fact, there is only a limited correla-
tion between the severity of endoscopic esophagitis and the 
severity and frequency of reﬂ  ux symptoms (Wiklund 1988, 
2001; Holtmann et al 2001; Dent et al 2005). For example, 
about half of individuals with dyspeptic symptoms may have 
a normal endoscopy (Modlin et al 2007). Endoscopically 
normal reﬂ  ux disease was deﬁ  ned by the Genval Workshop Therapeutics and Clinical Risk Management 2008:4(6) 1187
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Report (Armstrong et al 2004; Bardhan et al 2004a, b; 
Monnikes et al 2004; Stanghellini 2004b) as “GERD in 
patients who have no endoscopic evidence of Barrett’s 
esophagus or esophageal mucosal breaks.”(Armstrong 
et al 2004, Bardhan et al 2004a, b; Monnikes et al 2004; 
Stanghellini et al 2004a). These persons have typical GERD 
symptoms caused by reﬂ  uxed gastric contents, in the absence 
of visible esophageal mucosal injury as assessed by esopha-
gogastroendoscopy (EGD) (Armstrong et al 2004; Bardhan 
et al 2004a, b; Monnikes et al 2004; Stanghellini 2004; 
Stanghellini et al 2004). Indeed, the symptom proﬁ  le does 
not help the clinician to distinguish between NERD and 
EE, without there ﬁ  rst being an EGD performed. Thus, in 
all GERD patients, including those with NERD, symptom 
assessment in response to therapy is important.
Furthermore, in studies reporting on the clinical improve-
ment in the symptoms of GERD in subjects with EE, data 
will often be given of the proportion of persons improving 
or losing their symptoms, and the proportion of persons 
improving or losing their esophagitis. But these are not neces-
sarily the same individuals who both improve and who their 
endoscopic signs of disease. Why might this be important? 
A high proportion of GERD patients have an improvement 
or resolution of both symptoms and signs of their disease 
after 4–8 weeks’ therapy with a PPI, and yet unless they are 
maintained on continuous use PPI, many will have a recur-
rence of disease (approximately 80% in 6–12 months). We 
do not know whether persons with a given level of symptoms 
or endoscopic signs might heal completely in 4 rather than 
8 or 12 weeks of therapy.
Is there a subgroup of GERD patients, possibly as 
assessed by suitable measures of symptoms and endoscopic 
grade, who may be managed without maintenance PPI 
therapy and have a high probability of remaining in remis-
sion? On the other hand, is there an identiﬁ  able subgroup 
that needs to be maintained on full rather than half dose 
PPI? Furthermore, are there GERD sufferers who need 
longer periods of PPI treatment in order to enjoy complete 
resolution of their symptoms and normalization of their 
esophagus on endoscopy? The answers to these questions 
have important clinical and economic considerations. But 
more than that, perhaps if complete healing were achieved (in 
terms of both symptoms and where applicable, endoscopic 
signs), might the recurrence rate be lower, the need for 
maintenance PPI be less, and the patients’ Q of L be better? 
These are important and yet unresolved questions, that could 
not be studied until an appropriate assessment tool became 
available recently.
There is a small but appreciable treatment response 
to placebo in persons with GERD, with improvement in 
symptoms and signs in the patient in a clinical trial who is 
given placebo to compare with the outcome of acid lowering 
therapy. At the time of endoscopic study, the patient with 
previous EE may have fully or partially healed esophagitis. 
We know, for example from studies of prompt endoscopy 
in persons with previously undiagnosed dyspepsia where 
previous recent use of acid-lowering therapy was forbidden, 
that the proportion of subjects with more severe EE (LA C 
and D) is low (about 5%) (Thomson et al 2003), and yet in a 
long-term care facility the proportion of LA C and D subjects 
was 3- to 4-fold higher (Thomson et al 2003). In addition, 
reconsideration of the efﬁ  ciency and safety of so-called “on 
demand” therapy as a maintenance strategy for GERD has 
shown us that 0%–94% will have EE on subsequent EGD 
(Kuster et al 1994; Isolauri et al 1997; Manabe et al 2002; 
Pace et al 2004; Labenz et al 2006; Sontag et al 2006). It is 
controversial whether this relates to the natural history of 
GERD becoming endoscopically positive or negative, rather 
than NERD being a distinct non-continuum component of the 
GERD disorder (Fass et al 2001). Finally, even in persons 
with NERD, there may be subtle abnormalities when the 
mucosa is assessed by magnifying endoscopy or mucosal 
biopsy (Kiesslich et al 2004; Kato et al 2007). Thus, it is not 
clear that a so-called “normal” esophageal mucosa on EGD 
is in fact representative of tissue that is truly normal at the 
microscopic or even biochemical level.
Why do we need a new GERD 
questionnaire?
This question is raised in the title of a recent systematic 
review (Armstrong et al 2004) and has been considered in 
recent single topic monograph reviews (Armstrong et al 
2004; Stanghellini 2005; Bardhan et al 2007; Beckerling 
et al 2007; Monnikes et al 2007). Unfortunately, much time 
passed before it was accepted that the cluster of dyspeptic 
symptoms did not predict the cause of the patient’s pain or 
discomfort in the upper abdomen: persons with heartburn 
and regurgitation did not necessarily have EE on EGD, pain 
in the epigastric area improving or worsening with food and 
awakening the patient from sleep did not necessarily signify 
PUD, and symptoms of fullness, nausea and bloating were 
not necessarily associated with a normal EGD, and thus were 
speculated to be part of a motility disorder. This lack of corre-
lation between symptoms and the causes of dyspepsia forced 
the reconsideration of the importance of all dyspeptic symp-
toms as possibly being part of the spectrum of GERD.Therapeutics and Clinical Risk Management 2008:4(6) 1188
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Indeed, there was even the need to reﬁ  ne what we mean 
by the term “heartburn”, and accept that in some cultures 
there is no translation for this word. Vigorous discussions 
even ensued as to whether dyspepsia and GERD symptoms 
were one-in-the-same: Some of the arguments considered the 
observations that some persons with typical GERD symptoms 
often have NERD; indeed, typical “ulcer-like” symptoms 
were more likely to be associated with EE than with PUD; and 
there is extensive overlap in the symptoms of EE, PUD, and 
NERD (also sometimes previously called non-ulcer dyspep-
sia [NUD], or functional dyspepsia [FD]). It was no wonder 
then that there was much discussion about the semantics, and 
no surprise that the resulting confusion prevented us for so 
long from taking a step back, looking outside the box, and 
appreciating that what was important to the sufferer of GERD 
was the treatment-associated improvement in their trouble-
some symptoms: leave the EGD ﬁ  ndings to the endoscopist, 
and focus on the patient’s symptomatology.
Let us consider a shift in primary outcomes – endoscopists 
and therefore clinical trialists were quite able to reasonably 
accurately measure the diameter of a DU or GU, and we then 
became reasonably comfortable with the qualitative assess-
ment of the severity of EE, using a variety of scales of dam-
age, such as the new widely used LA or modiﬁ  ed LA scale 
(the same as the original LA A-D scale of EE, but including 
a descriptor for GERD symptoms but a normal endoscopy). 
However, one challenge remained: there is no tight correla-
tion between the severity of the GERD symptoms and the 
severity of EE. For example, from the severity of symptoms, 
the clinician cannot predict whether the EGD will be normal, 
whether there will be EE present, or what will be the severity 
of any associated LA A-D esophagitis. This was an issue with 
the use of H2-RAs, since these agents were slower and less 
effective than the PPIs in healing EE. But with the PPIs, all 
grades of EE from LA A to D are usually healed using stan-
dard unit doses of PPI once a day for 4–8 weeks. Healing of 
EE became an end in itself, not because this was necessarily 
associated with complete resolution of symptoms, but rather 
because it was expected that such healing would reduce the 
frequency and/or severity of stricture formation or reforma-
tion, or the development or even progression of Barrett’s 
epithelium, and therefore reduce the risk of development 
of dysplasia and esophageal adenocarcinoma. Such hopes 
have not always been substantiated. So, if healing of EE is 
not necessary for symptom improvement or complication 
prevention, then why aim to always achieve endoscopic heal-
ing of EE? Furthermore, EE may recur without symptoms, 
and symptom recurrence does not necessarily signify EE 
recurrence. Thus, when GERD symptoms recur, there may 
be the same, less, or more EE.
When a new therapeutic agent is being considered for 
formulary approval, a number of considerations are made, 
including safety and efﬁ  cacy of symptom improvement, 
healing of associated pathological changes, enhancement 
of Q of L, and cost. Different clinical trials will use various 
symptom scales, and not all of these have been validated for 
the GERD disease setting, nor are the healing of associated 
pathological changes, necessarily comparable. For example, 
of the 20 symptom assessment scales, only 5 have been 
evaluated (Table 1). Before symptom scales or Q of L instru-
ments can be accepted as primary endpoints by investigators, 
health-care decision-makers, or government/insurance pay-
ers, the scales must be evaluated to document their validity, 
reliability and responsiveness. Bardhan et al (2004b) have 
summarized the importance of psychometric validation: 
psychometric validation is essential for instruments used to 
assess surrogate markers (for example, GERD symptoms or 
Q of L), particularly when they are designed to be used as the 
primary outcome measure in clinical trials comparing two 
or more treatments. Two statements from the International 
Conference on Harmonization guidelines make the points: 
1) when a rating scale is used as the primary variable, it 
Table 1 Main characteristics of the identiﬁ  ed evaluative symptom scales
Name GERD-speciﬁ  c Multidimensional Self-assessed Daily assessed Available in different 
languages
Psychometrically 
validated
GERD Score 9 −− − − 9
UESS − 99 −− 9
GSAS 99 9 −− 9
GSRS −− 9 − 99
GRACI 9 − (9)∗ (9)∗ −−
Abbreviations: GERD, gastroesophageal reﬂ  ux disease; GRACI, GERD Activity Index; GSAS, GERD Symptom Assessment Scale; GSRS, Gastrointestinal Symptoms Rating 
Scale; UESS, Ulcer Esophagitis Subjective Symptoms Scale.
*Only parts of the scale.Therapeutics and Clinical Risk Management 2008:4(6) 1189
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is especially important to address factors such as content 
validity, inter- and intra-rater reliability and responsiveness 
for detecting changes in the severity of the disease; and 
2) if a trial … lacks assay sensitivity, it will fail to lead to a 
conclusion of efﬁ  cacy. In contrast …, the trial may ﬁ  nd an 
ineffective treatment to be non-inferior and could lead to an 
erroneous conclusion of efﬁ  cacy.
Speciﬁ  c aspects of GERD symptomatology need to be 
considered, especially when using generic versus disease-
speciﬁ  c questionnaires. But what in fact are the symptoms of 
GERD? Does the instrument measure esophageal as well as 
supra- and/or infra-esophageal symptoms, in addition to Q of 
L? Who administers the questionnaire, the health care worker 
or the patient? And what is the inter- and intra-investigator 
variability? Because so many large trails today are multicen-
tre and multinational, does the assessment instrument trans-
late well into various languages? What is the “background 
noise” of the score obtained in the questionnaire in normal 
persons not presenting with GERD? Because about half of 
GERD subjects have a normal endoscopy, then response to 
treatment cannot be measured by changes in the severity 
of erosions, and the availability of a validated, reliable and 
sensitive instrument to assess the symptoms, Q of L and 
response to therapy is therefore important (Armstrong et al 
2004; Bardhan et al 2004a).
Stanghellini et al systemically reviewed symptom scales 
for GERD from the perspective of their characteristics and 
psychometric quality, as well as the wide range of GERD 
symptoms. They considered what should be the main features 
of a valid symptom scale, what should be measured, when 
symptoms should be measured, and who should assess the 
symptoms (Table 2). Symptom measurement tools should 
be discriminative, predictive or evaluative instruments: 
“A discriminative instrument is intended to distinguish 
between patient groups, and to classify them according to 
the prevailing symptoms, including their severity and fre-
quency. If the assessment tool is to be used for diagnostic 
purposes, a discriminative questionnaire must be highly 
speciﬁ  c for the disease in question, whilst excluding other 
diseases with a high prediction probability. A predictive 
scale is used of a gold standard is available to estimate the 
likelihood of a speciﬁ  c disease or risk factors under deﬁ  ned 
circumstances. An evaluative scale is used to measure the 
magnitude of change in symptom severity, eg, over time, in 
one person, or in a group of persons. Its prime requirement 
is responsiveness, although validity and reproducibility are 
also necessary” (Stanghellini et al 2004, p. 4). The evaluative 
scale could be used, for example, to compare the results of 
one clinical trial with another. Because there are numerous 
symptoms experienced by GERD patients, and because the 
distribution of these symptoms may vary with the severity of 
EE (Table 3), a new assessment method is needed.
This review by Stanghellini et al (2004) demonstrated that 
5 of the evaluative symptom scales did not fulﬁ  ll all of the 
recommendations for an evaluative symptom scale (Table 1) 
(Stanghellini et al 2004) For example, only 3 of 5 were GERD 
speciﬁ  c, 2 were multidimensional, 3 were self-assessed, 1 was 
assessed daily, 1 was available in different languages, and 
4 were psychometrically validated (Stanghellini et al 2004) 
Given the limitations of the currently available evaluative 
symptom scales, there is clearly a need for a new evaluative 
symptom tool for the assessment of GERD symptoms during 
therapy, a scale that can be used in clinical trials of different 
therapeutic agents, to appropriately compare the treatment 
outcome of one medication with another. The ReQuest® 
questionnaire shows reliability, validity and ability to detect 
change; an ideal measurement instrument must be able “to 
determine the minimum change measured which has true 
“clinical relevance” as judged by the patient and his or her 
doctor” (Bardhan and Berghofer 2007, p. 99).
From a consideration of the literature, few evaluative 
scales fulﬁ  ll even some of these key characteristics. The 
GERD Symptom Assessment Scale is the most comprehen-
sive evaluative symptom scale to date (Stanghellini et al 
2004, 2006). It is a well-validated 15-item scale that includes 
associated as well as predominant GERD symptoms. It 
also assesses different symptom dimensions (frequency of 
episodes, intensity of symptoms, level of distress), and it is 
self-assessed twice, once before and once after treatment. 
However, this scale does not assess nocturnal symptoms of 
Table 2 Recommendations for an ideal GERD symptom assessment 
instrument suitable as a primary end-point for clinical trials
  1.  be sensitive in patients with GERD
  2.  cover the frequency and intensity of typical and atypical GERD 
symptoms
  3.  be multi-dimensional (cover all symptom dimensions)
  4.  have proven psychometric properties (validity, reliability, 
and responsiveness)
  5.  be practical and economic
  6.  be self-assessed (self-administered)
  7.  use “word pictures” which are easy to understand for patients
  8.  respond rapidly to changes (responsiveness over short time 
intervals)
  9.  be used daily to assess changes during and after therapy
 10.  be valid in different languages for international use 
Adapted with permission from Bardhan KD, Berghofer P. 2007. Look – but also listen! 
ReQuest™: An essay on a new validated scale to assess the outcome of GERD treat-
ment. Digestion, 75(Suppl):87–100. Copyright © 2007 S. Karger AG.Therapeutics and Clinical Risk Management 2008:4(6) 1190
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GERD, and it has not been tested in multinational clinical 
trials. Thus, there is only limited information on its respon-
siveness and transcultural validity. The Gastrointestinal 
Symptom Rating Scale (GSRS) is an evaluative, patient-
rated symptom scale, which is one of the most widely used 
GI-speciﬁ  c symptom scales in various settings (Achim et al 
2005a; Fass et al 2005; Stanghellini 2005). It was initially 
constructed for the evaluation of symptom severity in per-
sons with peptic ulcer disease and irritable bowel syndrome, 
and hence, it is not speciﬁ  c for GERD. All other evaluative 
symptom scales described in the literature have limitations 
such as lack of proven validity, are not self-assessed, com-
prise only predominant symptoms, or were developed for 
other purposes (Monnikes et al 2004; Achim et al 2005b; 
Beckerling et al 2007).
It is important to appreciate that a quarter to half of 
GERD patients do not have heartburn (Armstrong et al 2004; 
Bardhan et al 2004a; Stanghellini et al 2004; Monnikes et al 
2007) and about half of GERD patients have additional 
symptoms without having predominant heartburn (Armstrong 
et al 2004; Bardhan et al 2004a, b; Monnikes et al 2004; 
Stanghellini et al 2004). Only about a ﬁ  fth of patients with 
EE have heartburn during reflux episodes (Armstrong 
et al 2004; Bardhan et al 2004a, b; Monnikes et al 2004; 
Stanghellini 2004; Stanghellini et al 2004; Beckerling et al 
2004). The speciﬁ  cities of heartburn and regurgitation are 
89% and 95%, respectively, but the sensitivities are only 
about 38% and 6%, respectively (Klauser et al 1990), or 
even lower when there are atypical symptoms (Armstrong 
et al 2004; Bardhan et al 2004a; Beckerling et al 2004; 
Bardhan et al 2004b, 2005; Monnikes et al 2004, 2005a; 
Stanghellini 2004; Stanghellini et al 2004, 2005, 2006). 
Persons with GERD have a plethora of esophageal as well 
as supra- and infra-esophageal symptoms, and these may 
respond less predictably than do heartburn and regurgitation 
to acid-lowering therapy (Armstrong et al 2004; Bardhan et al 
2004a, b, 2005; Monnikes et al 2004; Beckerling et al 2004; 
Schoffel et al 2004; Stanghellini 2004; Stanghellini et al 
2004, 2005, 2006; Monnikes et al 2005a). It is possible that 
in the presence of predominant heartburn or regurgitation, 
these other symptoms may not be fully appreciated, and once 
the predominant symptoms are improved with therapy, the 
associated symptoms become more prominent. On the other 
hand, it is possible that once the predominant symptoms are 
improved, the associated symptoms become less bothersome, 
and are perceived to be milder.
GERD symptoms are episodic, and may vary even on a 
daily basis. For example, Kartman et al (2004) reported that 
there is a 40% probability that symptom levels will differ 
on successive days (Galmiche et al 1998; Jasani et al 1999). 
Thus, in a clinical trial, it is important for the symptoms to 
be assessed frequently, ideally on a daily basis, rather than 
just at the beginning and at the arbitrary end of the study. 
Finally, there is a poor inter-observer reliability of symptom 
assessment when physicians rather than the patients adminis-
ter a questionnaire (Rothman et al 2001) and self-assessment 
may be more reliable than external assessments (Locke et al 
1994; Rentz et al 2001). For example, physicians tend to 
underestimate the severity of patients’ symptoms (Stephens 
et al 1997).
Table 3 ReQuest™:  Validation (statistical results)
Statistical test What the test assesses Range 
of results
Results:   Threshold 
that needs 
to be exceeded 
or matched
Results obtained
erosive 
esophagitis
non erosive 
reﬂ  ux
Cronbach’s alpha Internal consistency 0 to 1 0.70 0.90 0.91
Intra-class correlation
coefﬁ  cient
Test-retest reliability* 0 to 1 0.70 LQ 0.94
SQ 0.86
LQ 0.89
SQ 0.78
Construct validity Correlation of prototype 
against existing instruments
−1 to 1 Approximately ± 0.5 GSRS 0.52
PGWB −0.48
(Spearman 
coefﬁ  cient)
GSRS 0.55
PGWB −0.39
(Pearson 
coefﬁ  cient)
Responsiveness index Quantiﬁ  es the ability to measure 
GERD symptom changes 
as a result of treatment
0 to inﬁ  nity 0.80 165 320
Abbreviations: *Reproducibility of the LQ & SQ is tested: LQ vs LQ, LQ vs SQ, SQ vs LQ, SQ vs SQ, LQ, Long questionnaire; SQ, short questionnaire; GSRS, gastrointestinal 
symptom rating scale; PGWB, pshchological general well being index scale. Reproduced with permission from Bardhan KD, Berghofer P. 2007. Look – but also listen! ReQuest™:  
An essay on a new validated scale to assess the outcome of GERD treatment. Digestion, 75 (Suppl): 87–100. Copyright © 2007 S. Karger AG.Therapeutics and Clinical Risk Management 2008:4(6) 1191
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The standards to be met in developing an instrument for 
teaching changes in GERD symptom in therapeutic trials 
have been summarized (Bardhan and Berghofer 2007). These 
standards recommended for an ideal GERD symptom assess-
ment instrument suitable as a primary end-point for clinical 
trials are outlined in Table 2. ReQuest™ has been subjected 
to validation using psychocentric testing and statistical test-
ing (Cronbach’s alpha, intra-class correlation co-efﬁ  cient, 
construct validity, and responsiveness index (Bardhan and 
Berghofer 2007) (Table 3).
Thus, the conceptual and psychometric requirements 
for a GERD symptom assessment questionnaire have 
been identiﬁ  ed (Armstrong et al 2004). In the next section 
(Section 3) is described the development of such an ideal 
tool, the ReQuest™ scale.
Development of the new 
questionnaire, ReQuestTM
The frequency and intensity of symptoms of GERD are poor 
predictors of the presence or severity of endoscopic changes 
(Ofman et al 2002; Johnson and Fennerty 2004). From a 
practical perspective, it has been suggested that GERD may 
be present when the person has heartburn on two or more 
days a week (Dent et al 1999). The primary aim of GERD 
treatment should be normalization of the sufferer’s quality 
of life through rapid and sustained resolution of esophageal 
and other GERD-associated symptoms (Revicki et al 1999). 
Secondarily, any associated esophagitis should be healed in 
the hope of fewer symptomatic recurrences, and the preven-
tion of the development or progression of complications such 
as strictures, Barrett’s epithelium, and esophageal adenocar-
cinoma. The treatment of GERD accomplishes the aim of 
improving symptoms, health-related Q of L, and mucosal 
healing (Prasad et al 2003).
The steps in the development of ReQuest™ have been 
reviewed (Armstrong et al 2004). GERD symptoms are 
heterogeneous, episodic and subjective (Modlin et al 2007). 
This becomes a matter of concern about the assessment of 
GERD symptoms in clinical trials, if symptom assessment 
is based only on the eradication of limited symptoms such 
as heartburn (which is itself often poorly deﬁ  ned) and if 
symptom assessment is made only, at ﬁ  xed time points such 
as study entry, (time 0), and at 2 and 4 weeks. Furthermore, 
in many clinical trials in GERD, the members investigative 
team rather than the patient assess the symptom response to 
PPI therapy (the patient’s perspective is the most important, 
and may be under-estimated by the investigators (Rothman 
et al 2001)).
In the ﬁ  rst step of the development of the ReQuest™ 
GERD questionnaire, the symptom spectrum of GERD and 
various symptom descriptions were investigated. To design 
ReQuest™, all identiﬁ  ed items typical (GERD symptoms 
and GERD-related complaints) from the literature and the 
interview surveys were reviewed. Different ways of describ-
ing the same thing were removed, leaving 67 items which 
were assigned to 6 different symptom dimensions (acid 
complaints, upper abdominal/stomach complaints, lower 
abdominal/digestive complaints, nausea, sleep disturbances, 
and other complaints).
A short and a long version of  ReQuest™ was developed. 
In the short version, the frequency of the dimensions was 
assessed using a 7-point Likert scale, and the intensity 
of the dimensions was assessed using a 100-mm visual 
analogue scale. The use of the Likert-type responses has 
been shown to produce higher internal consistency than 
dichotomized responses (Beckerling et al 2004; Monnikes 
et al 2004; Bardhan et al 2004b, 2005; Gillessen et al 2004; 
Naumburger et al 2004; Stanghellini 2004, 2005b, 2006; 
Monnikes et al 2005a). General well-being was added, and its 
intensity was assessed. A hierarchic logical order was used, 
reﬂ  ecting clinical practice, starting with the dimensions and 
then proceeding to the details. The symptom burden of the 
dimensions was measured by its frequency and/or intensity. 
The questionnaire was translated into different languages 
and then tested in focus groups. The ﬁ  rst step at validation 
was to perform an open study in 421 outpatients in Germany 
with endoscopically conﬁ  ned EE (LA grades A-D) given 
pantoprazole 20 mg daily for LA A, and pantoprazole 40 mg 
daily for LA B-D (BB 3,4). The long and short versions of 
the scale were applied on days –3, 0, 7, 14, 21, and 28, and 
on all other days, respectively. A second early clinical trial 
tested the prototype in 840 patients with NERD in Europe 
and Canada (Bardhan and Berghofer 2007).
The initial German version was translated into British 
English, American English, French and Spanish, using 
forward-, reconciliation-, and backward-translations. Focus 
group testing was undertaken in cities in 5 countries, and a 
preliminary validation of ReQuest™ was conducted in an 
open, multicentre German study. “The current version of 
ReQuest™ retained 60 of the original 67 items after factor 
analysis, ie, 7 symptom descriptions contributed little to the 
GERD symptom spectrum. These 60 items were clustered into 
20 factors, and these in turn correlated with the dimensions. 
Condensing items into dimensions is a pragmatic empirical 
process, whereas factor analysis is a mathematical one.” The 
factor analysis for the identiﬁ  cation of items that did not load Therapeutics and Clinical Risk Management 2008:4(6) 1192
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was performed 4 times. The dimensions were grouped into 
two subscales: the subscale ReQuest™-GI which reﬂ  ected acid 
complaints, stomach complaints, digestive complaints, and 
nausea, and the subscale ReQuest™-WSO which included the 
other dimensions reﬂ  ecting the aspects of well-being (general 
well-being, sleep disturbances and other complaints). The 
symptom pattern varies in patients with different endoscopic 
GERD grades (Table 4) (Bardhan et al 2007). For example, 
lower abdominal/digestive complaints and sleep disturbances 
are more prevalent in LA D than in LA A. The greatest symp-
tom changes occurred during the ﬁ  rst week of treatment with 
pantoprazole 20 and 40 mg, with the largest and most rapid 
decline being in the dimensions of acid and upper abdominal/
stomach complaints (Figure 1) (Bardhan et al 2004a).
The second phase of development of ReQuest™ was based 
on the data from the open study in 421 patients mentioned 
above and included internal consistency, test-rated reliability, 
and responsiveness (Monnikes et al 2004). Construct validity 
was studied by comparison with the GSRS and the Psychologi-
cal General Well-Being (PGWB) scale. Validation of ReQuest™ 
indicated a very high internal consistency (Cranbach’s 
∞ = 0.90) and test-related reliability (in correlation coefﬁ  cient 
0.94 [long-term] and 0.86 [short-term]). This was also the case 
for the two subscales of ReQuest™-GI and ReQuest™-WSO, 
with Cranbach’s ∞ coefﬁ  cients of 0.84 and 0.81, respectively. 
Responsiveness was high, with a responsiveness index of 0.8 
at day 28. Construct validity was good. Of importance, there 
was no association between the initial endoscopic GERD grade 
and the degree of correlation, indicating that the intensity of 
symptom load appears to be independent of the severity of the 
endoscopic grade. As noted previously, a similar lack of cor-
relation of clinical symptoms and endoscopic signs has been 
reported previously (Klauser et al 1990; Beckerling et al 2004; 
Monnikes et al 2004, 2005a; Gillessen et al 2004; Schoffel et al 
2004; Bardhan et al 2004b, 2005; Stanghellini 2004, 2005b, 
2006; Van Resburg et al 2005).
In addition to the ReQuest™ questionnaire (Stanghellini 
et al 2005), a GERD speciﬁ  c questionnaire has been devel-
oped to assess health-related Q of L (Holtmann et al 2005). 
These two sensitive and speciﬁ  c questionnaires have been 
used to assess the GERD patient’s satisfaction with PPI 
(Ferguson et al 2006).
Establishing a deﬁ  nition of symptom 
relief
ReQuest™ is being studied for its possible use to detect 
the minimum clinically important difference (MCID) in 
symptoms in GERD patients in PPIs. In clinical trials, 
“symptom relief ”, or time to ﬁ  rst or sustained symptom relief 
may be used, but mild background symptoms may occur 
(Bardhan and Berghofer 2007). A more stringent endpoint 
therefore is reduction of symptoms to below the background 
Table 4 Complete remission, endoscopically conﬁ  rmed healing and symptom relief rates (%) after 4, 8, and 12 weeks
Duration of treatment
4 weeks 8 weeks 12 weeks
Treatment ITT PP ITT PP ITT PP
Complete remission
 Pantoprazole 47 59 69 86 76† 93†
 Esomeprazole 49 62 70 84 76† 90†
 CI [−10.4, +∞][ −12.2, +∞][ −8.0, +∞][ −4.6, +∞][ −7.0, +∞][ −2.9, +∞]
Endoscopically 
conﬁ  rmed healing
 Pantoprazole 69 75 86 94 91 98*
 Esomeprazole 69 75 83 90 98 94*
 CI [−7.39, 7.69] [−8.08, 8.55] [−3.01, 8.68] [−0.80, 9.59] [−1.75, 9.59] [0.02, 7.27]
System relief
 Pantoprazole 63 76 77 90 79 95
 Esomeprazole 64 78 75 89 77 92
 CI [−8.8, 6.9] [−10.2, 6.0] [−5.3, 8.6] [−4.9, 6.8] [−4.7, 8.8] [−1.8, 7.9]
Abbreviations: ITT, intention to treat; PP, per-protocol; CI, conﬁ  dence interval of the difference.
*superiority of pantoprazole (CI above 0); †primary outcome criterion. Reproduced with permission from Bardhan KD,   Achim A, Riddermann T et al 2007.   A clinical trial 
comparing pantoprazole and esomeprazole to explore the concept of achieving ‘complete remission’ in gastro-oesophageal reﬂ  ux disease. Aliment Pharmacol Ther, 25:1461–69. 
Copyright © 2007 Blackwell Publishing Ltd.Therapeutics and Clinical Risk Management 2008:4(6) 1193
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level. The GERD symptom threshold was determined (Achim 
et al 2005b): the GERD symptom thresholds (95th percentile) 
in 385 healthy Germans was: ReQuest™, 5.04; ReQuest-GI, 
1.73; ReQuest – WSO, 3.88. In 2,032 subjects from the US, 
France, Spain, and Italy (Klauser et al 1990), similar scores 
were obtained (4.12, 1.60, and 2.87, respectively).
What is the symptom threshold, using ReQuest™, to 
deﬁ  ne symptom relief in GERD studies where the endos-
copy is either negative or positive? To answer this question, 
Stanghellini et al (2005a) recruited 385 individuals over the 
age of 18, who did not consider themselves as suffering regu-
larly from GERD symptoms, and who were not taking any 
medications for GERD. The intensity and frequency of seven 
dimensions of GERD symptoms were determined in these 
healthy volunteers, to calculate the ReQuest™, ReQuest™-
GI, and ReQuest™-WSO scores. The participants also com-
pleted the GSRS as well as the PGWB scale. The GERD 
symptom threshold was calculated as the 90th percentile of 
the ReQuest™ score in this population without evidence of 
GERD. GERD symptom thresholds were 3.37 for ReQuest™, 
0.95 for ReQuest™-GI, and 2.46 for ReQuest™-WSO.
This is an important concept, allowing the deﬁ  nition 
of what is in fact the normal range and upper limit of the 
ReQuest™ scores. This thereby establishes a benchmark for 
the deﬁ  nition of “symptom relief” in future treatment stud-
ies. It is therefore sufﬁ  cient to treat GERD patients until 
symptom burden is below the GERD symptom threshold 
seen in healthy persons.
A generally accepted deﬁ  nition of symptomatic relief 
in GERD was missing in the medical literature until the 
ReQuest™ tool was developed (Beckerling et al 2004). As 
pointed out by Beckerling et al (2004) the aim of GERD 
therapy is to achieve symptom relief and healing of esopha-
geal lesions. The importance of both of these endpoints was 
considered, and the steps in the development of the ReQuest™ 
symptom score were reviewed.
The next step was to develop the ReQuest™/LA Clas-
siﬁ  cation, a novel integrated approach for the comprehen-
sive assessment of treatment outcome in GERD (Bardhan 
et al 2005). The LA classiﬁ  cation of EE has four degrees 
of abnormality: A, B, C, and D. The ReQuest™ investiga-
tors added a ﬁ  fth grade, LA N (LA Normal), the common 
situation where EE is not present (ie, NERD). The vali-
dated subscale ReQuestTM-GI was rescaled to develop the 
ReQuest™ Symptom Classiﬁ  cation. Using log-linear regres-
sion, a transformation of ReQuest™-GI score was performed 
to establish a grading from 0 to 4, reﬂ  ecting the inﬂ  uence 
of symptoms on patients’ well-being (0: no disease value, 
score 0–1.70; 1: minor, score 1.71–3.79; 2: tolerable, score 
3.80–8.43; troublesome, score 8.44–18.75; 4: intense, score 
18.76–30.76). A matrix of ReQuest™/LA Classiﬁ  cation had 
both symptomatic and endoscopic classiﬁ  cations to provide 
an integrative index quantifying both relevant aspects of the 
clinical situation by identiﬁ  ers from 0N (symptoms: No dis-
ease value; lesions: Not present) to 4D (symptoms: Intense; 
lesions: Grade D) (Fass et al 2005). The authors suggest that 
“the new index enables the detailed clinical characterization 
of GERD patients at any stage and accurate assessment of 
treatment outcome by a single global measure. Furthermore, 
the index allows a standardized clinical assessment and a sim-
pliﬁ  ed comparison of the results of different clinical trials.”
Use of ReQuest™ in GERD patients 
with a normal endoscopy
“A shift in the management model from targeting structural 
abnormalities [minimal change esophagitis to LA A-D] and 
one dominant symptoms in GERD [eg heartburn] to focusing 
on the identiﬁ  cation and quantiﬁ  cation of a broad spectrum of 
symptoms [as in ReQuest™] has led to a reconsideration of our 
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Figure 1 Changes in gastro-oesophageal reﬂ  ux disease (GORD) related symptoms 
as assessed by ReQuest™ in an intention to treat population of 421 patients with 
GORD during treatment with pantoprazole 20 mg/day (Los Angeles [LA] Grade A) 
or 40 mg/day (LA grades B-D). Reproduced with permission from Bardhan KD, 
Stanghellini V, Armstrong D, et al. 2004a. Evaluation of GERD symptoms during 
therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion, 
69:229–37. Copyright © 2004 S. Karger AG.Therapeutics and Clinical Risk Management 2008:4(6) 1194
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current concepts of GERD” (Modlin et al 2007; Quigley et al 
2007). Indeed, the Genval workshop suggested that the deﬁ  -
nition of NERD includes persons with symptoms of GERD 
but who have not endoscopic evidence of erosion, ulceration 
or Barrett’s esophagus (Thomson et al 2003). Fass et al have 
deﬁ  ned NERD patients as having GERD symptoms, normal 
mucosa at EGD, plus acidic or weekly acidic intraesophageal 
reﬂ  ux (Fass et al 2001). High-resolution magniﬁ  cation EGD 
has demonstrated various subtle changes at the squamoco-
lumnar function of GERD patients with normal conventional 
EGD (Kiesslich et al 2004). This has led to the term “minimal 
change esophagitis” (Nakamura et al 2005).
About a quarter fewer NERD patients respond to a given 
symptomatic treatment compared with those GERD patients 
with esophageal erosions (Fass 2007). For example, Dean 
et al (2004) demonstrated in a systematic review that the 
PPI symptomatic pooled rate was 36.7 (95% conﬁ  dence 
interval [CI]: 34.1–39.3) in NERD patients and 55.5 (95% 
C1: 51.5–59.5) in those with EE. Therapeutic gain was 27.5% 
in NERD compared with 48.9% in EE. NERD patients’ 
symptoms respond equally to half as to full dose PPI, unlike 
those who have erosive esophagitis (Richter et al 2000). 
In 529 subjects with GERD symptoms but normal EGD 
(NERD) treated with P20 or E20, the median time to ﬁ  rst 
relief was 2 days, and 10–13 days for sustained relief (again, 
ITT, not statistically signiﬁ  cant (Monnikes et al 2007).
Use of ReQuest™ in GERD patients 
with erosive esophagitis (EE)
The placebo-response of GERD symptoms and EE is low. 
Initial studies with PPIs were focused on showing that 
they were superior to placebo or to H2-RAs in symptom 
improvement and EE healing. Then the commercial chal-
lenge was to demonstrate whether one PPI gave superior 
symptom control or EE healing than a competitor’s PPI. 
Clinical trials attempting to show the superiority of PPI-A 
versus PPI-B in healing EE can generally be achieved 
only with enrolment of thousands of GERD patients, the 
difference between the two healing rates is small, and the 
number of persons needed to treat (NNT) to achieve this 
superiority is large (eg, NNT of 15–20). The ability of a trial 
to show a difference in EE healing rates is also inﬂ  uenced 
by the proportion of subjects with more severe esophagitis 
(LA C/D), since healing rates with LA A/B are already so 
high (90%), that there is little room for improvement and 
therefore little opportunity for the delta value between the 
therapeutic beneﬁ  t of the two PPIs (PPI-A, PPI-B) to be 
statistically signiﬁ  cant.
The open study initially used to validate ReQuest™ 
comprised 421 endoscopy-positive GERD patients (ie, EE 
present), with a comparison of 2 doses of pantoprazole 
(Bardhan et al 2004; Monnikes et al 2004). Then, a double-
blind, randomized, parallel-group comparison was under-
taken in 45 centers across Germany, with 529 NERD patients 
treated with 20 mg pantoprazole or 20 mg esomoprazole 
over 4 weeks (Monnikes et al 2007). Using ReQuest™ in 
these patients with endoscopically normal GERD, there was 
no difference in the two treatments in terms of median time 
for the patients to achieve symptom relief (2 days for both 
pantoprazole and esomoprazole), and to sustained symptom 
relief (10 vs 13 days, p  0.05, powered to evaluate non-
inferiority). Furthermore, no statistically signiﬁ  cant differ-
ences were observed between the two treatment groups in the 
response to treatment according to the associated Heliobacter 
pylori status (Monnikes et al 2007). Symptom relief was 
deﬁ  ned as a ReQuest™ sum score below the GERD symptom 
threshold, as attained in Section 4 (recall that the symptom 
threshold had precisely been determined in a separate study 
of individuals without GERD) (Stanghellini et al 2005a). 
This approach is more precise than the simple presence or 
absence of one or more particular symptoms since it incorpo-
rates multiple symptom dimensions instead of single items, 
and was assessed daily by the patient rather than only at one 
point at the end of the 28-day treatment period.
Comparison of pantoprazole 
20 or 40 mg to placebo
A randomized, double-blind, multicenter, parallel-group 
comparison was performed in 386 patients with erosive 
GERD LA B-D (Monnikes et al 2005b). Treatment was for 
4 weeks. The values of clinically important differences for 
sum scores of ReQuest™ and ReQuest™-GI were signiﬁ  cantly 
different for pantoprazole versus placebo.
Comparison of pantoprazole
40 mg vs omeprazole 20 mg
Therapy was given to 261 matched pairs of symptomatic 
GERD patients, with endoscopic esophagitis scores of LA 
B-D (Naumburger et al 2004) As assessed by ReQuest™ and 
by the patient assessment of general well-being after 1 and 
2 weeks of therapy, pantoprazole (P) 40 mg daily was sig-
niﬁ  cantly superior to omeprazole (O) 20 mg daily. Patients 
enjoyed a signiﬁ  cantly lower symptom level with P40 versus 
O20 from day 2 onwards, and ﬁ  rst time to reach normal symp-
toms was achieved about 2 days faster in the pantoprazole 
than in the omeprazole group (p = 0.0298). Furthermore, Therapeutics and Clinical Risk Management 2008:4(6) 1195
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154 in the P40 group and 139 in the O20 group had 
sleep disturbances at baseline. Patients treated with P40 
suffered from less sleep disturbances after 1 and 2 weeks 
of therapy, as compare with those give O20 (Schoffel 
et al 2004). Data on healing rates of the associated EE 
were not provided.
Comparison of pantoprazole 
vs esomoprazole
Initial treatment
In a community based study of per protocol (PP) persons with 
dyspepsia undergoing EGD before being placed on therapy, 
approximately 45% had erosive esophagitis, 5% had peptic 
ulcer disease, and the remainder had a normal endoscopy 
(Thomson et al 2003). The prevalence of LA C/D esophagitis 
was approximately 10%. So, for every 1,000 dyspeptics, 450 
would have EE, of which 45 would have severe esophagitis, 
LA C/D.
In 529 patients with endoscopy-negative GERD receiv-
ing 20 mg pantoprazole or 20 mg esomeprazole, ReQuest™ 
symptoms scores were assessed daily for 14 days (Bardhan 
and Berghofer 2007; Monnikes et al 2007). The median 
time to ﬁ  rst symptom relief was 2 days for both drugs (ITT 
population), and the median time to sustained symptom relief 
(10 vs 13 days) was not signiﬁ  cantly different between the 
treatment groups.
In 561 ITT patients with LA A-D GERD, non-inferiority 
of pantoprazole vs esomeprazole 40 mg daily was shown 
(Glatzel et al 2007). However, the persons treated with 
pantoprazole for 28 days may have enjoyed “better healing”, 
since when PPI therapy was stopped, during the 7 day post 
treatment period, the proportion of patients experiencing a 
symptomatic relapse (51 vs 61%, p = 0.0216, ITT) and the 
number of symptomatic episodes (0.56 vs 0.71, p = 0.0095, 
ITT) were signiﬁ  cantly lower on pantoprazole than on esome-
prazole. In 2,316 persons with erosive esophagitis with either 
pantoprazole 40 mg (P40) or esomeprazole 40 mg (E40) 
daily, the median time to ﬁ  rst symptom relief was 2 days, 
and 5–6 days for sustained relief (ITT population, differences 
between P40 and E40 not statistically signiﬁ  cant (Bardhan 
and Berghofer 2007).
A total of 581 symptomatic subjects with LA A-D EE 
were randomized to pantoprazole 40 mg (P40) or esomo-
prazole 40 mg (E40) for 12 weeks in a double-blind, mul-
ticenter, parallel group comparison (Bardhan et al 2007). 
Symptom relief was considered to have been achieved if the 
score of the ReQuest™-GI fell below the predeﬁ  ned upper 
limit of the GERD symptom threshold. Neither on an ITT 
or a PP basis was there a difference between pantoprazole 
vs esomeprazole in complete remission, endoscopically 
conﬁ  rmed healing or symptom relief (Table 4) Symptom 
relief at 4, 8, and 12 weeks was similar in the two treatment 
arms, both on an intention-to-treat (ITT) and a per protocol 
basis (Achim et al 2005a) The endoscopic healing rates 
on an ITT basis were similar in P40 and E40 at 4, 8, and 
12 weeks, but P40 was higher than E40 PP healing rates at 
12 weeks. Including all subjects (LA A-D), the reduction in 
P40 was numerically but not statistically superior to E40 after 
12 weeks of treatment (p = 0.059), but for patients LA B-D, 
P40 was superior to E40 (p = 0.0029). Using the cumulative 
rates of complete remission (Bardhan et al 2005a) P40 was 
non-inferior to E40 at 4, 8, and 12 weeks.
Interestingly, in both treatment arms, a proportion of 
patients were inadequately treated after 8 weeks of therapy, 
with higher values of complete remission at 12 vs 8 weeks. 
This concept of the need for some subjects to be treated 
longer was strengthened by an open study of 934 LA A-D 
GERD subjects (Heading et al 2006). Treatment was for 
a maximum of 12 weeks, unless complete remission was 
achieved at 4 or 8 weeks (Gok et al 2007). There was an 
inverse relationship between the LA esophagitis grade and 
the complete remission rate at 4, 8, and 12 weeks (Table 5). 
Approximately one third of GERD LA B-D subjects had not 
achieved complete remission after 8 weeks treatment, and 
treatment for 12 weeks gave higher complete remission rates 
of 77.6%–82.7% (Table 6). Thus, it is clear that there is a 
sizable proportion of GERD patients who need 12 rather than 
the usual 8 weeks of PPI therapy in order to achieve complete 
healing, heating and symptom relief (Table 7).
The ReQuest™ database contains baseline and treat-
ment data from 14 clinical trials with symptom assessment 
Table 5 Symptom pattern in patients with different endoscopic 
GERD grades given as mean total score values dimension load
Dimension 
of ReQuest™
Grade A 
(n = 182)
Grade B 
(n = 130)
Grade C 
(n = 33)
Grade D 
(n = 4)
Acid complaints 85.2* 82.3 81.8 100
Upper abdominal/
stomach complaints
75.8 73.9 75.8 75.0
Lower abdominal/
digestive complaints
57.1 47.7 57.6 75.0
Nausea 37.9 38.5 39.4 50.0
Sleep disturbances 65.4 59.2 60.6 100
Other complaints 61.0 63.9 57.6 75.0
*Mean total score values, dimension load = frequency times intensity per protected, 
349 patients at baseline. After Heading et al 2006.Therapeutics and Clinical Risk Management 2008:4(6) 1196
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based on the reﬂ  ux questionnaire ReQuest™. The trials were 
designed to show the effect of different treatment regimens on 
symptom patterns in different patient populations (Thomson 
and Peter 2007). Demography and baseline characteristics 
between the two treatment groups were similar. Within the 
tested population (N = 3967) the mean scores for the acid 
dimension and the ReQuest™-GI for patients treated with 
pantoprazole 40 mg and esomeprazole 40 mg were lower 
on day 28 than at baseline (Table 8). In the acid dimension 
scores the mean pre-post differences were −2.12 (± 2.01) for 
pantoprazole 40 mg and −2.12 (± 2.12) for esomeprazole 40 
mg, resulting in a 9% difference between the pre-post differ-
ence values (Table 8). The differences between the scores of 
ReQuest™-GI were −5.33 (± 5.38) for pantoprazole 40 mg 
and −4.44 (± 4.97) for esomeprazole 40 mg (ie, 17%). For 
both scores the mean pre-post difference for patients treated 
with pantoprazole 40 mg signiﬁ  cantly exceeded the values 
for esomeprazole 40 mg (p  0.0001).
The patient population was divided into groups fol-
lowing the LA classiﬁ  cation for grades of GERD. Here, 
identical effects as for the whole study population were 
found for the dimension acid complaints. In the group of 
patients with GERD grade A the mean pre-post differences 
were −1.97 (± 1.94) for pantoprazole 40 mg and −1.78 (± 
1.90) for esomeprazole 40 mg (ie, 10%). Patients with GERD 
grade B showed pre-post differences of −2.49 (± 2.02) in 
the pantoprazole 40 mg treatment group and −1.87 (± 1.90) 
in the esomeprazole 40 mg treatment group, respectively 
(ie, 25%). The pre-post differences for patients with GERD 
grades C and D were −2.43 (± 2.03) for pantoprazole 40 mg 
and −2.05 (± 2.03) for esomeprazole 40 mg (ie, 16%). In all 
subgroups deﬁ  ned by GERD grade, the mean pre-post dif-
ferences for patients treated with pantoprazole 40 mg were 
signiﬁ  cantly higher that the differences for esomeprazole 
40 mg (p  0.0001 to p = 0.046) (Table 9).
The use of ReQuest™ questionnaire led to the greater 
appreciation of the importance of supra- and infra- esophageal 
symptoms, and the diversity of esophageal symptoms in 
persons with GERD, all of which impair the patients’ Q of L. 
The development of ReQuest™ questionnaire to asses both 
symptoms of GERD, QofL, and endoscopic changes based 
on the LA A-D grading of erosive esophagitis, led to the 
concept of complete healing, and pointed our attention to the 
potential need to treat some GERD patients for 12 weeks, or 
perhaps even longer. Recently presented studies published 
as yet only in abstract form highlight even more conceptual 
changes arising out of the ReQuest™ program: IBS symptoms 
are signiﬁ  cantly more frequent in NERD than in GERD 
patients with EE, and symptom burden is more severe in 
NERD with IBS than in EE with IBS (Monnikes et al 2008). 
Patients whose GI symptoms respond well to treatment tend 
to have a lesser overall symptom burden, a lesser quality 
of life impairment, and less psychological distress before 
treatment than those who respond less well to 4 to 8 weeks 
PPI therapy (Heading et al 2008). Finally, ReQuest™ and its 
subscales ReQuest-61™ and ReQuest-WSO™ were assessed 
in 1888 GERD patients before therapy with pantoprazole 
40 mg OD, and then at 4 and 8 weeks of therapy. A logistic 
regression was used to develop a model which predicted the 
response to PPI treatment with a probability of up to 80% 
(Heading et al 2008).
In summary, in the reporting of clinical trials, notes 
of healing of esophagitis and symptom relief are often 
reported separately, but when subjects with both healing 
and symptom relief are identiﬁ  ed, the percentages are 
lower than when each component is reported separately. 
This speaks to the importance of complete remission, and 
begs the question whether off-therapy recurrence rates are 
lower in those with complete healing, versus those with 
just symptom relief, or with endoscopic healing. This is 
but one of the many ways in which the ReQuest™ scale 
may be very useful in the design of future clinical trials. 
Now that the simpliﬁ  ed ReQuest in Practice® (Rubin et al 
2008) is available, this validated brief questionnaire “…has 
potential as an instrument for use in GERD patients,” seen 
in everyday clinical practice.
Table 7 Endpoints of symptom relief or healing at 4, 8, or 12 
weeks
Rates 4 8 12
Symptom relief 77 90 93
Healing rates 75 92 96
Complete healing 61 85 81
After Heading et al 2006.
Table 6 Complete remission rates (%) after 4, 8, and 12 weeks 
(per protocol population)
Patient group 4 weeks 8 weeks 12 weeks
NERD 64 83 90
Grade A esophagitis 62 81 88
Grade B esophagitis 43 66 83
Grades C/D esophagitis 32 64 78
After Heading et al 2006.Therapeutics and Clinical Risk Management 2008:4(6) 1197
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Concluding remarks
Perhaps it is worthwhile to take a historical perspective: 
initially acid-lowering therapy was used to manage patients 
with the then much more common cause of dyspepsia, PUD. 
The healing of the crater of the duodenal (DU) or gastric 
ulcer (GU) became the sought-after endpoint; symptom relief 
was often seen as being quite secondary. As the inclusion of 
Q of  L assessment slowly began to be included in the clinical 
trials of PPIs in PUD, the Nobel prize-winning recognition 
of the cure of many DU or GUs with the eradication of 
H. pylori, and the acknowledgement of the importance of the 
pathophysiological components providing gastro protection, 
lead to the greater use of co-therapy in high risk persons tak-
ing aspirin (ASA), non-steroidal anti-inﬂ  ammatory agents 
(NSAIDs), or coxibs. These two factors contributed to the 
already declining prevalence of DU/GU. Curiously, GERD 
slowly became more widely recognized, but the same nar-
row mindset that early on prevented some clinicians from 
accepting the role of H. pylori and NSAIDs in PUD, also 
prevailed initially in the design of PPI studies in patients 
with GERD.
“Other than in research studies, there [is] no pressing 
need for its use [ie, EGD] in day-to-day clinical practice 
to make the diagnosis of GERD or to distinguish 
between the different categories” (Bardhan and Berghofer 
2007 p. 89).
The proportion of persons with reﬂ  ux symptoms who 
have a normal endoscopy (ENRD) ranges from about 50% 
to 75% (Johansson et al 1986; Winters et al 1987; Jones et al 
1995; Lind et al 1997; Carlsson et al 1998; Galmiche et al 
1998; Ronkainen et al 2005).
The ReQuest™ database includes 14 clinical studies 
with 8,177 GERD patients in the ITT and 6,810 in the per 
protocol PP, comparing P40 with E40. ReQuest™ allowed 
the identiﬁ  cation of 1) a greater reduction the frequency 
and severity of symptoms on day 1 with P40 compared 
with E40 (32); 2) in patients with erosive esophagitis, 
there were fewer episodes of reﬂ  ux on P40 than E40 (33); 
3) on day 28 of PPI treatment, there was a greater reduc-
tion in ReQuest-GI with P40 than E40 (Goh et al 2007); 
and 4) greater reduction in sleep disturbance with P40 than 
E40 (Kato at al 2007).
Comparisons of large numbers of GERD subjects with 
erosive esophagitis have suggested, in post-randomization 
analysis, numerically higher healing rates of E40 versus 
P40 or L30 (lansoprazole 30 mg daily (REF , REF). If these 
differences were as great as 70% for E40 and 50% for P40/
L30, then 32/45 would heal on E40, and 23/45 would heal 
on the other PPIs.
Thus, 9/1,000 persons on E40 might possibly have a 
higher erosive healing rate, giving an NNT of about 100. 
If the number of persons in the community with EE were 
lower, or if the difference between healing rates for LA-C/D 
between two PPIs were less than 20%, the NNT would be 
even higher. Because of such a high value for NNT, it is no 
surprise that some governmental, professional or regulatory 
agencies have suggested that there is no clinically important 
difference between the PPIs. Whether this statement is true 
with the application of ReQuest/LA, and complete remission, 
remains to be established.
A maintenance study of 1450 GERD LA A-D patients 
initially treated 4–8 weeks on P40, randomization for the 
purpose of maintenance was undertaken with P20 or E20, and 
follow-up was 6 months (Kato et al 2007). No difference was 
seen in the treatment groups. In the Emancipate study (Goh 
et al 2007), 1303 patients with symptomatic LA A-D EE 
(were treated for healing of EE and “no” or “mild” heartburn 
and acid regurgitation) were randomized in a double blind 
manner for maintenance with pantoprazole 20 mg (P20) or 
esomeprazole 20 mg (E20) once daily for 6 months.
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Table 8 Mean pre-post differences between baseline and after 
28 days of treatment
Panto 40 mg Eso 40 mg Δ % p-value
Mean 
score (SD)
Mean 
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B −2.49 (± 2.02) −1.87 (± 1.90) 25 0.0001
C/D −2.43 (± 2.03) −2.05 (± 2.03) 16 0.025
After Thomson and Peter 2007.
aStandard deviation.Therapeutics and Clinical Risk Management 2008:4(6) 1198
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